BWX Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BWX Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $430.14M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $419.36M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $410.01M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $428.23M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $403.86M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $379.51M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $402.38M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $364.83M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $363.94M | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $358.97M | Feb 27, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $885.84M | Feb 23, 2026 |
| FY2025 | Sep 30, 2025 | $866.29M | Feb 23, 2026 |
| FY2025 | Jun 30, 2025 | $764.04M | Feb 23, 2026 |
| FY2025 | Mar 31, 2025 | $682.26M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $746.27M | Feb 23, 2026 |
| FY2025 | Sep 30, 2024 | $671.96M | Feb 23, 2026 |
| FY2025 | Jun 30, 2024 | $681.47M | Feb 23, 2026 |
| FY2025 | Mar 31, 2024 | $603.97M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $725.52M | Feb 24, 2025 |
| FY2024 | Sep 30, 2023 | $589.99M | Feb 24, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.99M | Feb 23, 2026 |
| FY2025 | Sep 30, 2025 | $82.11M | Feb 23, 2026 |
| FY2025 | Jun 30, 2025 | $78.39M | Feb 23, 2026 |
| FY2025 | Mar 31, 2025 | $75.46M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $71.02M | Feb 23, 2026 |
| FY2025 | Sep 30, 2024 | $69.48M | Feb 23, 2026 |
| FY2025 | Jun 30, 2024 | $72.97M | Feb 23, 2026 |
| FY2025 | Mar 31, 2024 | $68.47M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $65.89M | Feb 24, 2025 |
| FY2024 | Sep 30, 2023 | $60.27M | Feb 24, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.06M | Feb 23, 2026 |
| FY2025 | Sep 30, 2025 | $113.35M | Feb 23, 2026 |
| FY2025 | Jun 30, 2025 | $102.42M | Feb 23, 2026 |
| FY2025 | Mar 31, 2025 | $96.63M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $92.26M | Feb 23, 2026 |
| FY2025 | Sep 30, 2024 | $96.58M | Feb 23, 2026 |
| FY2025 | Jun 30, 2024 | $98.81M | Feb 23, 2026 |
| FY2025 | Mar 31, 2024 | $92.96M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $123.19M | Feb 24, 2025 |
| FY2024 | Sep 30, 2023 | $85.36M | Feb 24, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.87M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $7.48M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $7.61M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $9.54M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $11.06M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $14.19M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $17.67M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $15.22M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $7.19M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $6.41M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $394.42M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $318.66M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $279.69M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $234.28M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $230.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $231.17M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $216.77M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $214.09M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $210.15M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $209.51M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $479.85M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $408.43M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $363.70M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $244.70M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $386.03M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $196.44M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $279.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $169.29M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $221.96M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $239.91M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.56M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $153.65M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $151.29M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $198.31M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $311.05M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $255.03M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $182.12M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $109.34M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $96.88M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $52.63M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.27B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.87B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.75B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.62B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.50B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.29B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.91B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.66B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $1.71B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.58B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.79B | Feb 23, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.08B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $933.35M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $748.31M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $637.18M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $617.77M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $404.11M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $235.66M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $285.39M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $150.02M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $500.86M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $287.36M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $297.02M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $293.17M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $285.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $283.71M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $275.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $274.08M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $218.33M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $210.79M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.52B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.29B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.09B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.93B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.78B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.55B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.34B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.17B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $990.65M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $885.12M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $499.78M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $74.11M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $75.77M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $35.24M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $33.89M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $42.61M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $86.54M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $29.87M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $203.40M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $125.64M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $300.00M | Feb 24, 2016 |
| FY2015 | Dec 31, 2014 | $300.00M | Feb 24, 2016 |
| FY2014 | Dec 31, 2013 | $447.0K | Feb 26, 2015 |
| FY2013 | Dec 31, 2012 | $644.0K | Feb 26, 2014 |
| FY2012 | Dec 31, 2011 | $838.0K | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $2.62M | Mar 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 24, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 24, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 24, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 24, 2025 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.47M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $88.35M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $84.97M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $81.07M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $79.67M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $72.94M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $65.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $63.82M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $42.04M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $37.37M | Feb 25, 2019 |